Do Not Be So Quick To Blame Microbes On The Lab, The US FDA Warns Emcure
Emcure's Hinjwadi, India, plant should have investigated other more likely sources of contamination more thoroughly, the FDA says.
You may also be interested in...
The Quality Lowdown: Quality Vision Falls Short At Various US and Indian Facilities
Court overrides stem cell clinic’s dismissal of drug GMPs, the US FDA upbraids drug makers for quality unit shortfalls, and a variety of snafus trigger drug recalls.
Can Emcure’s Cut-Price Eribulin Dull Halaven In India?
Emcure has launched a generic version of Eisai’s cancer drug Halaven on the Indian market at a sharp 40% discount to the innovator product, and hopes to expand patient access significantly.
The Next New Thing In FDA Inspections: Poor Root Cause Investigations
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.